Polycythemia vera

Common Name(s)

Polycythemia vera

Polycythemia vera is a condition characterized by an increased number of red blood cells within the bloodstream. Affected individuals may also have excess white blood cells and platelets. These extra cells cause the blood to be thicker than normal. As a result, abnormal blood clots are more likely to form and block the flow of blood through arteries and veins. Individuals with polycythemia vera have an increased risk of deep vein thrombosis (DVT), a type of blood clot that occurs in the deep veins of the arms or legs. If a DVT travels through the bloodstream and lodges in the lungs, it can cause a life-threatening clot known as a pulmonary embolism (PE). Affected individuals also have an increased risk of heart attack and stroke caused by blood clots in the heart and brain. Polycythemia vera is associated with mutations in the JAK2 and TET2 genes. Most cases are not inherited, as the condition is associated with genetic changes that are somatic, which means they are acquired during a person's lifetime and are present only in certain cells.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Polycythemia vera" for support, advocacy or research.

Logo
MPDSUPPORT.ORG

Since 1994, our MPD-SUPPORT web site and free support email list offers interesting information on chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, myelodysplasia, and myelofibrosis. Anyone - patient, family member, or health professional, is welcome to join our growing list of subscribers. Our archives are available for you to research information.

http://www.mpdsupport.org

Last Updated: 14 Jan 2013

View Details
MPN Research Foundation

The primary mission of the MPN Research Foundation is to stimulate original research in pursuit of new treatments -- and eventually a cure -- for polycythemia vera, essential thrombocythemia and myelofibrosis, known collectively as myeloproliferative neoplasms (MPN).In addition, the MPN Research Foundation promotes collaboration in the scientific community to accelerate research, and serves as a powerful advocacy group for patients and their families

http://www.mpnresearchfoundation.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Polycythemia vera" returned 282 free, full-text research articles on human participants. First 3 results:

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
 

Author(s): A Tefferi, E Rumi, G Finazzi, H Gisslinger, A M Vannucchi, F Rodeghiero, M L Randi, R Vaidya, M Cazzola, A Rambaldi, B Gisslinger, L Pieri, M Ruggeri, I Bertozzi, N H Sulai, I Casetti, A Carobbio, G Jeryczynski, D R Larson, L Müllauer, A Pardanani, J Thiele, F Passamonti, T Barbui

Journal: Leukemia. 2013 Sep;27(9):1874-81.

 

Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis ...

Last Updated: 4 Sep 2013

Go To URL
Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.
 

Author(s): Anna L Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J Campbell, Anthony R Green

Journal: Haematologica. 2013 May;98(5):718-21.

 

Subclones homozygous for JAK2V617F are more common and larger in patients with polycythemia vera compared to essential thrombocythemia, but their role in determining phenotype remains unclear. We genotyped 4564 erythroid colonies from 59 patients with polycythemia vera or essential ...

Last Updated: 1 May 2013

Go To URL
Treatment target in polycythemia vera.
 

Author(s): Roberto Marchioli, Alessandro Maria Vannucchi, Tiziano Barbui

Journal: N. Engl. J. Med.. 2013 Apr;368(16):1556.

 

Last Updated: 18 Apr 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Polycythemia vera" returned 17 free, full-text review articles on human participants. First 3 results:

Neutrophilic dermatosis of the dorsal hands in a patient with polycythemia vera.
 

Author(s): Pedro de Vasconcelos, Luís Soares-Almeida, Paulo Filipe

Journal: Acta Dermatovenerol Alp Panonica Adriat. 2013 ;22(2):53-4.

 

Last Updated: 9 Jul 2013

Go To URL
[Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
 

Author(s): Megumi Funakoshi-Tago

Journal: Yakugaku Zasshi. 2011 ;131(8):1183-7.

 

It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. The somatic JAK2 mutation (V617F) ...

Last Updated: 1 Aug 2011

Go To URL
Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera.
 

Author(s): Claire Harrison

Journal: Hematology Am Soc Hematol Educ Program. 2010 ;2010():129-34.

 

The seminal discovery of the JAK2V617F mutation, which is highly prevalent in Philadelphia-negative myeloproliferative disorders, now renamed neoplasms, triggered an almost unprecedented explosion of interest and data in the field. Descriptions of additional mutations in exon 12 of ...

Last Updated: 17 Jan 2011

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
 

Status: Recruiting

Condition Summary: Polycythemia Vera; Essential Thrombocythemia

 

Last Updated: 24 Mar 2014

Go to URL

Last Updated: 2 Apr 2014

Go to URL
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
 

Status: Recruiting

Condition Summary: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia

 

Last Updated: 22 Feb 2013

Go to URL